Eli Lilly and Company

LLY

735.19 (0.36%) 2.62

660.01(B)

Health Care

Pharmaceuticals

Eli Lilly and Company discovers develops and markets human pharmaceuticals in the United States Europe China Japan and internationally. The company offers Basaglar Humalog Humalog Mix 75/25 Humalog U-100 Humalog U-200 Humalog Mix 50/50 insulin lispro insulin lispro protamine insulin lispro mix 75/25 Humulin Humulin 70/30 Humulin N Humulin R and Humulin U-500 for diabetes; Jardiance Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products including Alimta Cyramza Erbitux Jaypirca Retevmo Tyvyt and Verzenio. In addition the company offers Olumiant for rheumatoid arthritis atopic dermatitis severe alopecia areata and COVID-19; Taltz for plaque psoriasis psoriatic arthritis ankylosing spondylitis and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder diabetic peripheral neuropathic pain generalized anxiety disorder fibromyalgia and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals Inc.; F. Hoffmann-La Roche Ltd and Genentech Inc.; Biologics Inc. AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co. Ltd as well as Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis Indiana.

My Holdings:

(?% ownership)

Cost basis:

Market cap:$660.01(B)

EV:$714.86(B)

Total Equity:$18.35(B)

Div. yield:0.76%

Earnings date:Oct-30-2025

P/E:47.93

P/E (fwd):32.20

P/FCF:134.90

P/S:12.41

P/B:36.09

EPS:$15.3

EPS (fwd):$22.8

FCF/share:$5.5

Dividend/share:$5.6

Book value/share:$20.4

ROIC:27.3%

ROA:16.0%

ROE:86.7%

Gross margin:82.6%

Net margin:25.9%

Valuation Summary TTM Financials Growth Estimates Historical Data KPIs Similar Companies Ownership Tools

LLY Valuation & Price Targets

Current Price

$735

Day change: +0.36%

PEvaluation

N/A

Analyst targets

N/A

More Valuation Methods

DCF (2-stage)

N/A

DCF (simple)

N/A

DCF (exit mult.)

N/A

Future P/E

N/A

Peter Lynch FV

N/A

Graham No.

N/A

DDM

N/A

PEvaluation

5% overvalued

Low

$524

Mid

$698

High

$873

Current price

$735

Fair P/E

Margin of safety

Market Model

Economic moat: Very wide

EPS Estimates

	Low	Avg	High	#
FY+1	21.9	22.8	25.7	25
FY+2	26.2	30.3	35.8	27
FY+3	31.6	37.0	43.6	22
FY+4	34.5	42.8	48.2	12
FY+5	36.0	48.3	54.6	12

EPS

Analyst Price Targets

19% undervalued

Low

$650

Mid

$876

High

$1190

Current price

$735

Analyst Recommendations

Strong Buy3

Buy18

Hold8

Sell0

Strong Sell0

EPS Estimates

	Low	Avg	High	#
FY+1	21.9	22.8	25.7	25
FY+2	26.2	30.3	35.8	27
FY+3	31.6	37.0	43.6	22
FY+4	34.5	42.8	48.2	12
FY+5	36.0	48.3	54.6	12

2-stage DCF

First Stage Duration
Starting Free Cash Flow
First Stage Growth Rate
Terminal Growth Rate
Discount Rate

Discounted Cash Flow

Forecast years
Terminal Growth Rate
Discount Rate

Free cash flow estimates:

Y+1 est.

Y+2 est.

0.00%

Y+3 est.

0.00%

Y+4 est.

0.00%

Y+5 est.

0.00%

Discounted Cash Flow (exit mult.)

Forecast years
Exit FCF Multiple
Discount Rate

Free cash flow estimates:

Y+1 est.

Y+2 est.

0.00%

Y+3 est.

0.00%

Y+4 est.

0.00%

Y+5 est.

0.00%

Future P/E Valuation

Projection Years
Base Revenue
Revenue Growth Rate
Final Net Margin
Final P/E Ratio
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate

Dividend Discount Model

Annual Dividend
First Stage Length (Years)
First Stage Growth Rate
Final Growth Rate
Discount Rate

Summary

TTM Financials

Income (TTM)

Revenue$53.26(B)

Gross profit$44.01(B)

EBITDA$24.78(B)

Net income$13.80(B)

Gross margin82.6%

Operating margin42.8%

Net margin25.9%

Shares outstanding:897.74(M)

Balance sheet

Total assets$100.92(B)

Current assets$49.85(B)

Total liabilities$82.57(B)

Current liabilities$39.02(B)

Cash & Short-term inv.$3.55(B)

Long-term debt$34.26(B)

Total intangibles$11.68(B)

PP&E$20.53(B)

Cash flow (TTM)

FCF$4.88(B)

CapEx$-6.05(B)

Dividends paid$-5.03(B)

Stock issued$0

Stock repurchased$-4.39(B)

Stock-based comp.$613.90(M)

Debt issued$11.43(B)

Debt repaid$-1.07(B)

Per share data (TTM)

Growth Estimates

Revenue

CAGR: 13.4%

FY+1$61.71(B)

FY+2(+18.5%)$73.12(B)

FY+3(+15.7%)$84.63(B)

FY+4(+10.4%)$93.42(B)

FY+5(+9.3%)$102.11(B)

Net Income

CAGR: 19.9%

FY+1$20.52(B)

FY+2(+32.4%)$27.17(B)

FY+3(+21.6%)$33.05(B)

FY+4(+14.1%)$37.71(B)

FY+5(+12.6%)$42.47(B)

EPS

CAGR: 20.6%

FY+1$22.83

FY+2(+32.5%)$30.25

FY+3(+22.4%)$37.04

FY+4(+15.6%)$42.81

FY+5(+12.9%)$48.34

FCF per share

CAGR: 33.0%

FY+1$17.71

FY+2(+95.4%)$34.60

FY+3(+8.9%)$37.67

FY+4(+36.1%)$51.27

FY+5(+8.2%)$55.48

Historical Financials

Showing limited histrical data.

Upgrade to access 10+ years of financials!

YearlyQuarterly

Income

Revenue Operating Income Net IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomePre-tax incomeIncome tax

Cash flow

Stock-based Comp. FCFCFONet IncomeD&ACFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures

Balance sheet

Total Assets Total LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EIntangible AssetsGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity

Per share data

EPS (Basic) FCF/Share Dividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share

Ratios

P/E P/S EV/EarningsP/FCFP/BEV/FCFDebt/EquityPayout ratio

Margins

Net Income Margin Operating Margin Gross MarginEBITDA MarginFCF Margin

Returns

ROIC ROAROCEROE

Shares outstanding

Shares (Basic)Shares (Diluted)

Market Cap.

KPIs

Revenue By Geography

Rest of World US Europe China Japan

Revenue By Segment

Neuroscience Immunology Cardiovascular Oncology Animal Health Diabetes Other

Similar Companies

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.16%
Institutions: 83.89%
Other: 15.94%

Institutional ownership

Trading Summary

In the past year, insiders have bought $2.89(M) worth of the company's stock, and sold $1.07(B).

Congress members have bought between $87010 - $305000 worth of the company's stock, and sold between $114023 - $535000.

Insider transactions

2025-10

$0.00

2025-09

$0.00

2025-08

$783762

$2.89(M)

2025-07

$225.42(M)

$0.00

2025-06

$0.00

2025-05

$1.65(M)

$0.00

2025-04

$0.00

2025-03

$205.14(M)

$0.00

2025-02

$585.13(M)

$0.00

2025-01

$0.00

2024-12

$0.00

2024-11

$723042

$0.00

2024-10

$0.00

	Date	Shares	Total ($)	Price ($)	Name	Title
Buy	2025-08-12	117	75,018	641.2	SULZBERGER GABRIELLE	Director
Buy	2025-08-12	1,565	1,005,242	642.3	FYRWALD J. ERIK	Director
Buy	2025-08-12	1,632	1,052,263	644.8	RICKS DAVID A	Chief Executive Officer
Buy	2025-08-12	1,000	634,405	634.4	SKOVRONSKY DANIEL	Officer
Sell	2025-08-11	1,250	783,762	627.0	YUFFA ILYA	Officer
Buy	2025-08-08	200	127,913	639.6	JACKSON JAMERE	Director
Sell	2025-07-24	280,000	225,419,259	805.1	LILLY ENDOWMENT, INC.	Beneficial Owner of more than 10% of a Class of Security
Grant	2025-07-21	6	4,958	826.3	SULZBERGER GABRIELLE	Director
Grant	2025-07-21	19	14,834	780.7	LUCIANO JUAN R	Director
Grant	2025-07-21	13	9,917	762.8	FYRWALD J. ERIK	Director
Grant	2025-07-21	13	9,917	762.8	HEDLEY MARY LYNNE	Director
Grant	2025-07-21	15	11,750	783.3	ALVAREZ RALPH	Director
Grant	2025-06-16	6	4,959	826.5	SULZBERGER GABRIELLE	Director
Grant	2025-06-16	18	14,834	824.1	LUCIANO JUAN R	Director
Grant	2025-06-16	12	9,916	826.3	FYRWALD J. ERIK	Director
Grant	2025-06-16	12	9,916	826.3	HEDLEY MARY LYNNE	Director
Grant	2025-06-16	14	11,750	839.3	ALVAREZ RALPH	Director
Sell	2025-05-27	1,000	716,410	716.4	ZAKROWSKI DONALD A	Officer
Grant	2025-05-19	6	4,958	826.3	SULZBERGER GABRIELLE	Director
Grant	2025-05-19	19	14,833	780.7	LUCIANO JUAN R	Director
Grant	2025-05-19	13	9,917	762.8	FYRWALD J. ERIK	Director
Grant	2025-05-19	13	9,917	762.8	HEDLEY MARY LYNNE	Director
Grant	2025-05-19	15	11,750	783.3	ALVAREZ RALPH	Director
Sell	2025-05-14	1,250	936,550	749.2	YUFFA ILYA	Officer
Grant	2025-05-02	17,875	0	0.0	HAKIM ANAT	General Counsel
Grant	2025-04-21	6	4,958	826.3	SULZBERGER GABRIELLE	Director
Grant	2025-04-21	18	14,833	824.1	LUCIANO JUAN R	Director
Grant	2025-04-21	12	9,917	826.4	FYRWALD J. ERIK	Director
Grant	2025-04-21	12	9,917	826.4	HEDLEY MARY LYNNE	Director
Grant	2025-04-21	14	11,750	839.3	ALVAREZ RALPH	Director
Grant	2025-03-17	6	4,958	826.3	SULZBERGER GABRIELLE	Director
Grant	2025-03-17	17	14,833	872.5	LUCIANO JUAN R	Director
Grant	2025-03-17	12	9,917	826.4	FYRWALD J. ERIK	Director
Grant	2025-03-17	12	9,917	826.4	HEDLEY MARY LYNNE	Director
Grant	2025-03-17	14	11,750	839.3	ALVAREZ RALPH	Director
Sell	2025-03-13	1,000	818,240	818.2	ZAKROWSKI DONALD A	Officer
Sell	2025-03-03	220,000	204,326,151	928.8	LILLY ENDOWMENT, INC.	Beneficial Owner of more than 10% of a Class of Security
Sell	2025-02-25	225,000	203,190,794	903.1	LILLY ENDOWMENT, INC.	Beneficial Owner of more than 10% of a Class of Security
Sell	2025-02-24	60,432	53,425,407	884.1	LILLY ENDOWMENT, INC.	Beneficial Owner of more than 10% of a Class of Security
Sell	2025-02-21	99,452	87,786,505	882.7	LILLY ENDOWMENT, INC.	Beneficial Owner of more than 10% of a Class of Security
Sell	2025-02-20	14,685	12,893,353	878.0	LILLY ENDOWMENT, INC.	Beneficial Owner of more than 10% of a Class of Security
Grant	2025-02-20	460	0	0.0	DOZIER ERIC	Officer
Sell	2025-02-19	9,985	8,771,285	878.4	LILLY ENDOWMENT, INC.	Beneficial Owner of more than 10% of a Class of Security
Grant	2025-02-18	5	4,958	991.6	SULZBERGER GABRIELLE	Director
Grant	2025-02-18	17	14,833	872.5	LUCIANO JUAN R	Director
Grant	2025-02-18	11	9,917	901.5	FYRWALD J. ERIK	Director
Grant	2025-02-18	11	9,917	901.5	HEDLEY MARY LYNNE	Director
Grant	2025-02-18	13	11,750	903.8	ALVAREZ RALPH	Director
Sell	2025-02-13	35,446	31,175,396	879.5	LILLY ENDOWMENT, INC.	Beneficial Owner of more than 10% of a Class of Security
Sell	2025-02-10	5,000	4,316,065	863.2	SKOVRONSKY DANIEL	Officer
Grant	2025-02-10	7,123	6,189,335	868.9	YUFFA ILYA	Officer
Grant	2025-02-10	5,974	5,190,812	868.9	HERNANDEZ EDGARDO	Officer
Grant	2025-02-10	6,815	5,921,593	868.9	RAU DIOGO	Chief Technology Officer
Grant	2025-02-10	7,170	6,230,302	868.9	JONSSON PATRIK	Officer
Grant	2025-02-10	919	798,957	869.4	DOZIER ERIC	Officer
Grant	2025-02-10	6,828	5,933,469	869.0	WHITE ANNE E	President
Grant	2025-02-10	2,895	2,516,217	869.2	MONTARCE LUCAS E	Chief Financial Officer
Grant	2025-02-10	18,771	16,310,400	868.9	SKOVRONSKY DANIEL	Officer
Grant	2025-02-10	6,103	5,303,491	869.0	VAN NAARDEN JACOB S.	Officer
Grant	2025-02-10	10,320	8,967,672	869.0	HAKIM ANAT	General Counsel
Grant	2025-02-10	55,131	47,902,710	868.9	RICKS DAVID A	Chief Executive Officer
Grant	2025-02-10	1,359	1,181,381	869.3	ZAKROWSKI DONALD A	Officer
Sell	2025-02-06	210,000	183,567,262	874.1	LILLY ENDOWMENT, INC.	Beneficial Owner of more than 10% of a Class of Security
Grant	2025-01-21	6	4,958	826.3	SULZBERGER GABRIELLE	Director
Grant	2025-01-21	19	14,834	780.7	LUCIANO JUAN R	Director
Grant	2025-01-21	13	9,916	762.8	FYRWALD J. ERIK	Director
Grant	2025-01-21	13	9,916	762.8	HEDLEY MARY LYNNE	Director
Grant	2025-01-21	15	11,750	783.3	ALVAREZ RALPH	Director
Grant	2024-12-16	12	9,917	826.4	SULZBERGER GABRIELLE	Director
Grant	2024-12-16	19	14,834	780.7	LUCIANO JUAN R	Director
Grant	2024-12-16	12	9,667	805.6	JOHNSON KIMBERLY H	Director
Grant	2024-12-16	12	9,917	826.4	HEDLEY MARY LYNNE	Director
Grant	2024-12-16	15	11,750	783.3	ALVAREZ RALPH	Director
Grant	2024-11-18	316	229,917	727.6	SULZBERGER GABRIELLE	Director
Grant	2024-11-18	302	220,000	728.5	BAICKER KATHERINE	Director
Grant	2024-11-18	322	234,833	729.3	LUCIANO JUAN R	Director
Grant	2024-11-18	320	233,089	728.4	FYRWALD J. ERIK	Director
Grant	2024-11-18	315	229,666	729.1	JOHNSON KIMBERLY H	Director
Grant	2024-11-18	302	220,000	728.5	WALKER KAREN SAMMIS	Director
Grant	2024-11-18	302	220,000	728.5	JACKSON JAMERE	Director
Grant	2024-11-18	302	220,000	728.5	KAELIN WILLIAM G JR	Director
Grant	2024-11-18	316	229,917	727.6	HEDLEY MARY LYNNE	Director
Grant	2024-11-18	318	231,750	728.8	ALVAREZ RALPH	Director
Sell	2024-11-08	900	723,042	803.4	ZAKROWSKI DONALD A	Officer
Grant	2024-10-31	4,302	0	0.0	VAN NAARDEN JACOB S.	Officer
Grant	2024-10-21	11	9,967	906.1	SULZBERGER GABRIELLE	Director
Grant	2024-10-21	16	14,498	906.1	LUCIANO JUAN R	Director
Grant	2024-10-21	11	9,967	906.1	JOHNSON KIMBERLY H	Director
Grant	2024-10-21	11	9,967	906.1	HEDLEY MARY LYNNE	Director
Grant	2024-10-21	13	11,780	906.2	ALVAREZ RALPH	Director
Grant	2024-09-16	11	10,159	923.5	SULZBERGER GABRIELLE	Director
Grant	2024-09-16	16	14,777	923.6	LUCIANO JUAN R	Director
Grant	2024-09-16	10	9,235	923.5	JOHNSON KIMBERLY H	Director
Grant	2024-09-16	11	10,159	923.5	HEDLEY MARY LYNNE	Director
Grant	2024-09-16	13	12,006	923.5	ALVAREZ RALPH	Director
Grant	2024-09-11	5,835	0	0.0	SKOVRONSKY DANIEL	Officer
Sell	2024-09-03	24,084	23,281,840	966.7	LILLY ENDOWMENT, INC.	Beneficial Owner of more than 10% of a Class of Security
Sell	2024-08-27	24,552	23,777,668	968.5	LILLY ENDOWMENT, INC.	Beneficial Owner of more than 10% of a Class of Security
Sell	2024-08-26	750	712,500	950.0	ZAKROWSKI DONALD A	Officer
Sell	2024-08-22	3,196	3,088,382	966.3	LILLY ENDOWMENT, INC.	Beneficial Owner of more than 10% of a Class of Security
Grant	2024-08-20	13,727	0	0.0	RICKS DAVID A	Chief Executive Officer
Grant	2024-08-19	11	10,140	921.8	SULZBERGER GABRIELLE	Director
Grant	2024-08-19	16	14,749	921.8	LUCIANO JUAN R	Director
Grant	2024-08-19	10	9,218	921.8	JOHNSON KIMBERLY H	Director
Grant	2024-08-19	11	10,140	921.8	HEDLEY MARY LYNNE	Director
Grant	2024-08-19	13	11,984	921.8	ALVAREZ RALPH	Director

Congressional trading

2025-10

$0.00

2025-09

$0.00

2025-08

$0.00

2025-07

$0.00

2025-06

$32501

$8001

2025-05

$16001

$24002

2025-04

$64503

$32501

2025-03

$8001

2025-02

$83001

$0.00

2025-01

$8001

$83001

2024-12

$56004

$8001

2024-11

$48502

$0.00

2024-10

$8001

$32501

	Date	Politician	Party	Chamber	Amount ($)
Buy	2025-06-06	Ro Khanna	D	House	$1,001 - $15,000
Sell	2025-06-03	Jonathan L. Jackson	D	House	$15,001 - $50,000
Sell	2025-05-30	Gilbert Ray Cisneros, Jr.	D	House	$1,001 - $15,000
Buy	2025-05-14	Marjorie Taylor Greene	R	House	$1,001 - $15,000
Sell	2025-05-13	Josh Gottheimer	D	House	$1,001 - $15,000
Buy	2025-05-05	Marjorie Taylor Greene	R	House	$1,001 - $15,000
Buy	2025-05-01	Josh Gottheimer	D	House	$1,001 - $15,000
Buy	2025-04-21	Jonathan L. Jackson	D	House	$15,001 - $50,000
Sell	2025-04-21	Bruce Westerman	R	House	$1,001 - $15,000
Sell	2025-04-15	Tommy Tuberville	R	Senate	$15,001 - $50,000
Sell	2025-04-09	Josh Gottheimer	D	House	$1,001 - $15,000
Sell	2025-04-08	Rob Bresnahan	R	House	$1,001 - $15,000
Sell	2025-04-07	Julie Johnson	D	House	$1,001 - $15,000
Sell	2025-03-10	Josh Gottheimer	D	House	$1,001 - $15,000
Buy	2025-03-03	Bruce Westerman	R	House	$1,001 - $15,000
Sell	2025-02-19	Josh Gottheimer	D	House	$1,001 - $15,000
Sell	2025-02-10	Ron Wyden	D	Senate	$50,001 - $100,000
Buy	2025-01-22	Ron Wyden	D	Senate	$50,001 - $100,000
Buy	2025-01-21	Marjorie Taylor Greene	R	House	$1,001 - $15,000
Sell	2025-01-08	Josh Gottheimer	D	House	$1,001 - $15,000
Buy	2024-12-24	Marjorie Taylor Greene	R	House	$1,001 - $15,000
Sell	2024-12-18	Josh Gottheimer	D	House	$1,001 - $15,000
Sell	2024-12-16	Josh Gottheimer	D	House	$1,001 - $15,000
Sell	2024-12-13	Josh Gottheimer	D	House	$1,001 - $15,000
Sell	2024-12-12	Josh Gottheimer	D	House	$1,001 - $15,000
Sell	2024-12-11	Josh Gottheimer	D	House	$1,001 - $15,000
Sell	2024-12-10	Josh Gottheimer	D	House	$1,001 - $15,000
Sell	2024-12-09	Josh Gottheimer	D	House	$1,001 - $15,000
Sell	2024-11-19	Josh Gottheimer	D	House	$1,001 - $15,000
Sell	2024-11-14	Josh Gottheimer	D	House	$1,001 - $15,000
Sell	2024-11-08	Greg Landsman	D	House	$15,001 - $50,000
Buy	2024-10-30	Sheldon Whitehouse	D	Senate	$15,001 - $50,000
Sell	2024-10-16	Josh Gottheimer	D	House	$1,001 - $15,000

Tools

Dividend Income

Investment Amount
Dividend Yield

What is the Dividend Income Calculator?

The Dividend Income Calculator helps you estimate the yearly, quarterly, monthly, and daily income of your investments.

How to Use This Calculator?

Enter the dividend yield and the invested amount. Optionally, preload stock data to automatically fetch the dividend yield.

Required Investment

Dividend Yield
Desired Yearly Payout
Desired Quarterly Payout
Desired Monthly Payout

What is the Required Investment Calculator?

The Required Investment Calculator helps you determine the amount of money you need to invest in a stock to achieve a desired dividend.

How to Use This Calculator?

Enter the dividend yield and your desired dividend income. Optionally, preload stock data to automatically fetch the dividend yield.

Future Dividend Yield

Base Dividend
Current Price
Number of Years
Dividend Growth Rate

What is the Future Yield Calculator?

The Future Yield Calculator helps you estimate the future dividend yield of a stock based on its current dividend, price, and expected dividend growth rate.

How to Use This Calculator?

Enter the base dividend, current price, number of years, and dividend growth rate. Optionally, preload stock data to automatically fetch the dividend and price. The calculator will display the current yield and the projected future yield.

Future Dividend Income

Base Dividend
Number of Years
Dividend Growth Rate

What is the Future Dividend Income Calculator?

The Future Dividend Income Calculator helps you estimate the future dividend income from your investments based on the current dividend yield and expected growth rate.

How to Use This Calculator?

Enter the current dividend yield, expected growth rate, and investment duration. Optionally, preload stock data to automatically fetch the dividend yield.

About

Terms & privacy

Price charts & news courtesy of TradingView

Blog

Contact